• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

LSD Conference Recap: IMIO Life

Microdose by Microdose
March 17, 2022
in Events
Reading Time: 2 mins read
A A
LSD Conference Recap: IMIO Life

IMIO Life is a psychedelic medicine company based in Israel, “dedicated to finding novel solutions for debilitating neurological disorders affecting millions of patients and their families. The approach is to combine known molecules with our unique drug delivery technology, enabling better penetration of molecules into the brain, reducing the therapeutic dose, providing a safer treatment while minimizing adverse effects”

Dr. Tal Hasson, Chief Technology Officer, led a presentation on Overcoming the Lingering Effects of LSD at our recent LSD Conference. Dr. Hasson gave a very in-depth look at how LSD works in the body and the brain, with the goal of optimizing future delivery mechanisms. Here are some highlights. 

“…we can see that LSD doesn’t stay in the brain for long. It’s out of the brain, but not out of the system..”

“So what is happening is that LSD is concentrated and settles within the digestive tract and it takes it a longer time to actually get eliminated from the digestive tract. So one of the assumptions that we’re thinking of is that it’s not only that you have a slow dissociation of LSD from the 5HT2A. It’s also discontinued. Leakage. Probably into the circulatory system and then re-penetration of the brain.”

[bsa_pro_ad_space id=2]
ADVERTISEMENT
Lasix Mail Order

“So if you combine these two factors together you are going to get a prolonged effect. And then your therapeutic window is going to be much wider, then if you were trying to find out how to treat something in a short duration..”

Continue on your trip...

Wonderland 2023 Review: PsychMD

Microdose Announces Dr. Sam Clark, CEO of Terran Biosciences, as Wonderland 2023 Keynote Presenter

The World on Drugs: Documentary Premiere at Wonderland

“Imagine you were able to exclusively target the brain, and thereby minimize the systemic exposure. Then that gives you another level of confidence in which you can probably lower the therapeutic dose. And if we look at the fact that we have a complicated molecule, an expensive molecule — so if we can further reduce the therapeutic dose, which would be much more effective and potentially lowering the price of the drug.”

Very important analysis for the future of delivering future therapeutic treatments at scale.

See below for a look at the Q&A with Dr. Hasson. And check out IMIO’s website here for more information on their work.

 

[bsa_pro_ad_space id=2]
ADVERTISEMENT
Tags: IMIO
Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Next Post
A Closer Look at MindBio Therapeutics

A Closer Look at MindBio Therapeutics

Please login to join discussion

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.